Trastuzumab deruxtecan,Capecitabine,Paclitaxel
Daiichi Sankyo,AstraZeneca
['t-dxd']
dr. yale bar shows that more biopsies chance of a her2 low result and as previously seen, t-dxd may be effective in her2 ihc 0/ultra low. repeat biopsies can be painful &amp; costly &amp; i do think our selection process for t-dxd will change. will we even need to test?? #asco23 
Breast & gyn med onc @valleyhealthnj. Opinions my own. Host of INTERLUDE podcast 🎤 Co-lead @cosmocollab. Focus on survivorship and social media in oncology.